These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 19074101

  • 1. Induction therapy in multiple myeloma.
    Harousseau JL.
    Hematology Am Soc Hematol Educ Program; 2008; ():306-12. PubMed ID: 19074101
    [Abstract] [Full Text] [Related]

  • 2. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [Abstract] [Full Text] [Related]

  • 3. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.
    Cancer; 2010 Jul 01; 116(13):3143-51. PubMed ID: 20564642
    [Abstract] [Full Text] [Related]

  • 5. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.
    Biol Blood Marrow Transplant; 2010 Jan 01; 16(1):70-7. PubMed ID: 19733251
    [Abstract] [Full Text] [Related]

  • 6. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, Patriarca F, Hajek R, Spencer A, Boccadoro M, Palumbo A.
    Lancet Oncol; 2015 Dec 01; 16(16):1617-29. PubMed ID: 26596670
    [Abstract] [Full Text] [Related]

  • 7. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A, Attal M, Roussel M.
    Clin Cancer Res; 2011 Mar 15; 17(6):1253-63. PubMed ID: 21411441
    [Abstract] [Full Text] [Related]

  • 8. Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
    Lee JH, Lee JH, Kim DY, Kim SD, Choi Y, Kang YA, Seol M, Lee KH.
    Eur J Haematol; 2012 Jun 15; 88(6):478-84. PubMed ID: 22364526
    [Abstract] [Full Text] [Related]

  • 9. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
    Kobayashi T, Kuroda J, Fuchida S, Murakami S, Hatsuse M, Okano A, Iwai T, Tsutsumi Y, Kamitsuji Y, Akaogi T, Kawata-Iida E, Shimizu D, Uchiyama H, Matsumoto Y, Horiike S, Nakao M, Takahashi R, Kaneko H, Uoshima N, Kobayashi Y, Shimazaki C, Taniwaki M.
    Intern Med; 2013 Jun 15; 52(9):961-8. PubMed ID: 23648714
    [Abstract] [Full Text] [Related]

  • 10. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.
    J Clin Oncol; 2010 Feb 10; 28(5):800-7. PubMed ID: 20048187
    [Abstract] [Full Text] [Related]

  • 11. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
    Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.
    Clin Transplant; 2009 Feb 10; 23(6):839-47. PubMed ID: 20447186
    [Abstract] [Full Text] [Related]

  • 12. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pégourié B, Kolb B, Stoppa AM, Fuzibet JG, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traullé C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau JL.
    Blood; 2011 Nov 24; 118(22):5752-8; quiz 5982. PubMed ID: 21849487
    [Abstract] [Full Text] [Related]

  • 13. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D, Li J, Huang BH, Liu JR, Zou WY, Su C.
    Chin Med J (Engl); 2012 Dec 24; 125(24):4454-9. PubMed ID: 23253719
    [Abstract] [Full Text] [Related]

  • 14. Integrating novel therapies in the transplant paradigm.
    Harousseau JL.
    Cancer J; 2009 Dec 24; 15(6):479-84. PubMed ID: 20010167
    [Abstract] [Full Text] [Related]

  • 15. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Sahebi F, Frankel PH, Farol L, Krishnan AY, Cai JL, Somlo G, Thomas SH, Reburiano E, Popplewell LL, Parker PM, Spielberger RT, Kogut NM, Karanes C, Htut M, Ruel C, Duarte L, Murata-Collins JL, Forman SJ.
    Biol Blood Marrow Transplant; 2012 Mar 24; 18(3):486-92. PubMed ID: 22198542
    [Abstract] [Full Text] [Related]

  • 16. Evolving role of stem cell transplantation in multiple myeloma.
    Harousseau JL, Moreau P.
    Clin Lymphoma Myeloma; 2005 Sep 24; 6(2):89-95. PubMed ID: 16231846
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
    Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, Pezzatti S, Ferrari S, Liberati AM, Oliva S, Patriarca F, Offidani M, Omedé P, Montefusco V, Petrucci MT, Giuliani N, Passera R, Pietrantuono G, Boccadoro M, Corradini P, Palumbo A.
    Blood; 2013 Aug 22; 122(8):1376-83. PubMed ID: 23775712
    [Abstract] [Full Text] [Related]

  • 18. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M, Agrawal N, Yadav N, Verma P, Ahmed R, Mehta P, Kapoor J, Bhurani D.
    Ann Hematol; 2018 Oct 22; 97(10):1869-1877. PubMed ID: 29781040
    [Abstract] [Full Text] [Related]

  • 19. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
    Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández MT, de Arriba F, Gutiérrez NC, Martín-Ramos ML, Cibeira MT, Mateos MV, Martínez J, Alegre A, Lahuerta JJ, San Miguel J, Bladé J, Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group.
    Blood; 2012 Aug 23; 120(8):1589-96. PubMed ID: 22791289
    [Abstract] [Full Text] [Related]

  • 20. Advances in therapy of multiple myeloma.
    Bladé J, Rosiñol L.
    Curr Opin Oncol; 2008 Nov 23; 20(6):697-704. PubMed ID: 18841053
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.